{
    "code": "52027326",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027326",
    "time": "2023-04-07 05:38:45",
    "許可證字號": "衛部藥輸字第027326號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "112\/03\/05",
    "發證日期": "107\/03\/05",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202732601",
    "中文品名": "免瘤諾 膠囊2.3毫克",
    "英文品名": "NINLARO Capsules 2.3 mg",
    "適應症": "1.合併 lenalidomide 及 dexamethasone 用於接受過至少一線治療的多發性骨髓瘤成年病人。\r\n2.多發性骨髓瘤成年病人接受自體幹細胞移植後的維持治療。\r\n3.多發性骨髓瘤成年病人未接受幹細胞移植的維持治療。",
    "劑型": "130膠囊劑",
    "包裝": "2-1000顆PVC-AL-AL鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "新成分",
    "監視期限": "112\/03\/05",
    "主成分略述": "Ixazomib citrate",
    "限制項目": "02輸　入 1S須執行確認性療效臨床試驗 5F免除銜接性試驗",
    "申請商名稱": "1406701100  台灣武田藥品工業股份有限公司",
    "申請商地址": "台北市信義區松高路1號17樓",
    "主製造廠": [
        {
            "製造廠名稱": "FDE9023000  HAUPT PHARMA AMAREG GMBH",
            "製造廠廠址": "DONAUSTAUFER STRABE 378, 93055 REGENSBURG, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FGB0219100  ANDERSONBRECON (UK) LTD",
            "製造廠廠址": "UNITS 2-7, WYE VALLEY BUSINESS PARK, BRECON ROAD, HAY-ON-WYE, HEREFORD, HEREFORDSHIRE, HR3 5PG, UNITED KINGDOM",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED KINGDOM",
            "製程": "次包裝廠"
        },
        {
            "製造廠名稱": "FGB0401000  ANDERSONBRECON (UK) LIMITED",
            "製造廠廠址": "UNIT 1, TALGARTH BUSINESS PARK, TREFECCA ROAD, TALGARTH, BRECON, POWYS, LD3 0PQ, UNITED KINGDOM",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED KINGDOM",
            "製程": "包裝"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005950",
            "成分名稱": "Ixazomib citrate",
            "含量描述": "(equivalent to ixazomib......2.3MG)",
            "含量": "3.2900000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "仿單核定本_1100823_中文仿單_Ninlaro_USPI_v202103_TW (clean) - Final A3-110-08-23.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027326&Seq=003&Type=9"
        },
        {
            "title": "020273260005-107-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027326&Seq=004&Type=8"
        },
        {
            "title": "020273260004-107-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027326&Seq=003&Type=8"
        },
        {
            "title": "020273260003-107-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027326&Seq=002&Type=8"
        },
        {
            "title": "020273260002-107-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027326&Seq=001&Type=8"
        }
    ]
}